Company / Operating Cash Flow
UroGen Pharma Ltd. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$162.4M
FY2025
5-year range
-$162.4M / -$76.4M
FY2021-FY2025
Trend
-112.7%
vs FY2024
Sector context
#152 of 216
Health Care
What the data says
At -$162M, UroGen Pharma Ltd.'s operating cash flow ranks #152 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$162M in FY2025 to $4M in FY2016.
Based on SEC 10-K filings.
-$162M in FY2025.
Declined from -$88M to -$162M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#152 of 216 in Health CareTop 70% of 216This company -$162.4M Sector average $658.7M
▼
-124.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 112.7% year-over-year.
- Ranks #152 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$162.4M | -112.7% |
| FY2024 | -$76.4M | +12.8% |
| FY2023 | -$87.6M | -3.1% |
| FY2022 | -$84.9M | +0.0% |
| FY2021 | -$84.9M | -19.5% |
| FY2020 | -$71.0M | -642.2% |
| FY2019 | -$9.6M | +74.4% |
| FY2018 | -$37.3M | -290.2% |
| FY2017 | -$9.6M | -328.4% |
| FY2016 | $4.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026